Perioperative Inflammation and Breast Cancer Outcome

Samsung Medical Center1,568 enrolled

Overview

It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results. surgery is main cause of inflammation for cancer patients. Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,568

Conditions

Breast Neoplasms

Interventions

NSAIDS (ketorolac and ibuprofen)DRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Breast cancer patients who took the surgery Exclusion Criteria: * underlying medical disease (major heart disease, lung disease, coagulopathy) * major psychologic disease (major depression, schizophrenia, manic disorder) * pregnancy * rheumatic disease patients

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

disease free survival

Time frame: 5 years

Secondary Outcomes

overall survival

Time frame: 5years

Central Contacts

Se Kyung Lee, M.D.

CONTACT

82-10-3014-0110 sekyung.lee@samsung.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.